Hospira Inc

Most Recent

  • uploads///GEVA ALXN LAL D
    Miscellaneous

    Backing Out of the Synageva BioPharma Deal, Part 3

    Things like acts of war and natural disasters aren’t MACS unless they disproportionately affect Synageva relative to other early-clinical-stage biopharmaceutical companies.

    By Brent Nyitray, CFA, MBA
  • uploads///XAL over
    Healthcare

    Merger must-knows: The shareholder vote and 90% tender condition

    Once the SEC approves the proxy, a vote is scheduled. Usually, the last condition for a deal is the vote of the target shareholders.

    By Brent Nyitray, CFA, MBA
  • uploads///SLXP VRX SLXP basics
    Miscellaneous

    The Salix–Valeant merger: Basics of Salix Pharmaceuticals

    Xifaxin is by far Salix’s largest product, accounting for ~70% of its revenues in 2013. Xifaxin is a big reason for the Salix–Valeant merger transaction.

    By Brent Nyitray, CFA, MBA
  • uploads///PE ratio
    Earnings Report

    Key Factors That Impact Johnson & Johnson’s Forward Valuation

    Two factors expected to impact Johnson & Johnson’s forward valuation are increasing competition for Olysio and further decline in international revenues.

    By Nicole Sario
  • uploads///chart
    Macroeconomic Analysis

    Alternative ETFs’ Investment Strategy Guide

    A liquid alternative ETF, the ProShares Large Cap Core Plus ETF (CSM) tracks a long-short index of Credit Suisse 130/30.

    By Ivan Kading
  • uploads///SLXP VRX SLXP at a glance
    Miscellaneous

    Parsing the Salix–Valeant merger MAC clause: Part 1

    In the deal between Salix Pharmaceuticals and Valeant, the MAC clause lays out the circumstances under which Valeant can back out of its deal with Salix.

    By Brent Nyitray, CFA, MBA
  • uploads///SLXP VRX GI
    Miscellaneous

    Parsing the Salix–Valeant merger MAC clause: Part 2

    Pretty much anything that has a material adverse effect on the company will be considered a MAC, but there will be exceptions to that rule.

    By Brent Nyitray, CFA, MBA
  • uploads///PCYC ABBV ABBV basics
    Miscellaneous

    The Pharmacyclics–AbbVie Merger: The Basics of AbbVie

    A major reason for the Pharmacyclics–AbbVie merger is to diversify AbbVie away from its reliance on a single product, Humira, and boost its pipeline.

    By Brent Nyitray, CFA, MBA
  • uploads///FSL NXPI Spread Analysis
    Miscellaneous

    The Freescale–NXP merger: A large deal in the semiconductor space

    The key to the Freescale–NXP merger is the timing. The companies are guiding to a 2H15 close, likely in the fourth quarter.

    By Brent Nyitray, CFA, MBA
  • uploads///FSL NXPI FSL basics
    Miscellaneous

    The Freescale–NXP Merger: Freescale at a glance

    The Freescale–NXP merger is driven by complementary offerings. Freescale is active in the auto, consumer, networking, and industrial markets.

    By Brent Nyitray, CFA, MBA
  • uploads///CI ANTM downside
    Miscellaneous

    Is the Cigna-Anthem Merger a Setup?

    Cigna has been put ‘in play,’ which means other buyers will be taking a look. The spread is wide, but there are major unanswered questions. It makes sense to give this one a wide berth.

    By Brent Nyitray, CFA, MBA
  • uploads///CI ANTM combination
    Miscellaneous

    Anthem Files Bear Hug Letter for Cigna on June 21

    On June 21, Anthem (ANTM) filed a bear hug letter for Cigna (CI). A bear hug letter is a formal press release in which an acquiring company discloses its interest in a target company.

    By Brent Nyitray, CFA, MBA
  • uploads///Geographic exposure
    Company & Industry Overviews

    Central Nervous System Is Key to Teva’s Specialty Medicines

    Revenues for Teva’s (TEVA) Specialty Medicines segment grew by 2.1% to $8,560 million in 2014, from $8,388 million in 2013.

    By Nicole Sario
  • uploads///SLXP VRX SLXP products
    Miscellaneous

    The Salix–Valeant merger MAC clause: Part 3

    If these carve-outs affect Salix in a disproportionate way compared to other pharma companies, then it is still a MAC and Valeant can back out of the deal.

    By Brent Nyitray, CFA, MBA
  • uploads///BHI HAL next steps
    Miscellaneous

    More on the Baker Hughes and Halliburton merger MAC clause

    This article further discusses the MAC clause in the Baker Hughes and Halliburton merger agreement.

    By Brent Nyitray, CFA, MBA
  • uploads///Chart
    Macroeconomic Analysis

    Examining the SPY ETF and how US Stocks Performed in 2015

    As we enter 2016, let’s review how Wall Street and US stocks, represented here by the SPDR S&P 500 ETF (SPY), responded to global events throughout 2015.

    By Renee Blakely
  • uploads///Graph Part
    Company & Industry Overviews

    How are XLV’s Moving Averages Trending?

    Out of 56 stocks in XLV’s portfolio, a total of 32 stocks were trading above their 20-day moving average.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    Biotechnology Traded below Moving Averages in Last Week of August

    Biotechnology and pharmaceuticals are the two largest subgroups of XLV. In the biotechnology subgroup, 100% of the stocks are trading below their 20-day, 50-day, and 100-day moving averages.

    By Peter Neil
  • uploads///Graph Part
    Company & Industry Overviews

    The Biotech Sector Is in a Downward Long-Term Trend

    Though most of the biotech stocks rebounded from the recent lows, the long-term trend for biotech seems to be heading downward.

    By Peter Neil
  • uploads///Leverage ratios
    Company & Industry Overviews

    Teva’s Debt Levels – Best among Competitors

    In terms of debt-to-EBITDA, Teva is well placed at 2.0x–2.5x to maintain a low credit risk. This will allow Teva to use debt for acquisitions and growth.

    By Nicole Sario
  • uploads///Branded Portfolio
    Company & Industry Overviews

    3 Key Therapeutic Segments Drive Branded Revenues

    Actavis’s North American Brands segment revenue increased significantly by 336% year-over-year to $4,631.4 million in 2014 from $1,062.5 million in 2013.

    By Nicole Sario
  • uploads///Penetration
    Company & Industry Overviews

    What’s Supporting Continued Growth in the Generics Market?

    The global generics market was valued at $168 billion in 2013. From 2013 to 2018, it’s expected to grow at a CAGR of 11% to reach $283 billion.

    By Nicole Sario
  • uploads///Complex generics
    Company & Industry Overviews

    Complex Generics Are Attractive Due to High Margins

    Complex generics are large and complex formulations or active ingredients used to treat chronic and life threatening diseases like cancer, Hepatitis C, and HIV.

    By Nicole Sario
  • uploads///NTE
    Company & Industry Overviews

    Specialty Generics: Why Are They Getting More Attention?

    There are two categories of specialty generics – NTE (New Therapeutic Entities) and Complex Generics. In this part of the series, we’ll discuss NTE.

    By Nicole Sario
  • uploads///SPLS ODP background
    Miscellaneous

    Don’t trade the Office Depot spread like a typical arb spread

    Once the proxy comes out, check the transaction background and see if they ran an auction. If not, a private equity buyer may step in after the deal breaks.

    By Brent Nyitray, CFA, MBA
  • uploads///SPLS ODP upside downside
    Miscellaneous

    Handicapping the risk-reward balance of the Office Depot deal

    Staples stock was up on the announcement, and the analyst community understands the pressure this segment is under. At any rate, no Staples vote is needed.

    By Brent Nyitray, CFA, MBA
  • uploads///HSP PFE rationale
    Miscellaneous

    Hospira–Pfizer merger: Benefits from growing biosimilars market

    One of the major drivers for the Hospira–Pfizer transaction is the expected growth of the sterile injectables and biosimilar markets.

    By Brent Nyitray, CFA, MBA
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.